A new report found that while more than 90% of health systems have deployed third-party AI tools, less than half have the infrastructure to properly test and validate them before they become embedded in patient care. The post Hospitals Are All In on AI, but Testing and Oversight Haven’t Caught Up appeared first on MedCity News.

Biohaven is outlicensing to SK Biopharmaceuticals global rights to opakalim, a Kv7-targeting small molecule in pivotal clinical testing for epilepsy. Biohaven gets non-dilutive financing for its pipeline while SK Bio gains another asset to potentially commercialize in the U.S. The post SK Bio Broadens U.S. Prospects, Licensing Late-Stage Epilepsy Drug From Biohaven appeared first on MedCity News.

When the healthcare system defaults to uncertainty, people delay care because it feels safer for their wallets. In some cases, people wait too long, leaving an ER visit as the path of least resistance.  The post The Missing Piece in Lowering the Cost of Care: Predictability appeared first on MedCity News.

More than a dozen health systems are warning patients of a phishing campaign impersonating Epic’s MyChart portal with fake Medicare rewards and faux login pages. Experts say the scam exposes a deeper problem: patients can’t be expected to spot increasingly polished fakes, so the responsibility falls on providers to communicate in ways that build trust. The post Epic MyChart Phishing Scam Hits Health Systems: What Providers Should Do appeared first on MedCity News.

Roivant Sciences subsidiary Priovant Therapeutics received FDA approval for Lisraya as a treatment for the rare inflammatory disorder dermatomyositis. Licensed from Pfizer, this once-daily pill designed to block JAK1 and TYK2 proteins is also in clinical development for three additional rare immunological disorders, each with blockbuster potential. The post FDA Nod for Inflammation Drug Notches Wins for Rare Disease Patients, Roivant’s Biz Strategy appeared first on MedCity News.

Chronic wounds demand clinicians willing to act outside of their defined role, not because the system incentivizes it, but because without it, the wound will not heal. The post The Silent Epidemic: Why Diabetic Foot Ulcers Have Been Overlooked for Three Decades appeared first on MedCity News.

We are on the cusp of an age of anticipatory medicine, an explosion in our ability to read the body’s signals and catch the killers before they do their damage. The post Reading the Body’s Signals: AI’s Ultimate Healthcare Opportunity appeared first on MedCity News.

AstraZeneca and Amgen drug Tezspire met the goals of a Phase 3 test in eosinophilic esophagitis (EoE), a chronic disorder whose only approved biologic therapy is Sanofi’s Dupixent. An approval for Tezspire in EoE would be its third indication, bolstering sales of the blockbuster product. The post AstraZeneca, Amgen Drug Moves Closer to Competing With Dupixent in a New Indication appeared first on MedCity News.

Datavant launched a new provider exchange platform, which replaces fax-based record requests with a digital workflow. It aims to give care teams real-time visibility into request status while easing the administrative burden on clinical staff. The post Datavant’s New Platform Could Cut Record Retrieval Time from Days to Hours appeared first on MedCity News.

It’s time we reignite treatment development for sepsis and other immune-mediated conditions that strike when patients are most vulnerable.  The post Precision Medicine Transformed Oncology —It’s Time to Do the Same for Sepsis appeared first on MedCity News.

Consumer drug platforms and how they fit into the rise of the consumer in healthcare will be part of the conversation at INVEST Digital Health, scheduled for October 29 in Dallas. Register today! The post What Do the Latest Iteration of Consumer Drug Platforms Offer? appeared first on MedCity News.

Onos Health’s Series A funding round was led by Costanoa, with support from Flare Capital Partners and CVS Health Ventures. The post Onos Health Raises $17M to Expand AI-Powered Behavioral Health Platform appeared first on MedCity News.

Boston Scientific disclosed a cyberattack disrupting its global IT systems and order shipping capabilities, with the company unable to provide a timeline for when normal operations will resume. The disclosure adds the medical device giant to a growing list of medtech companies — including Stryker, Medtronic and Abbott — hit by major cyberattacks this year. The post Cyberattack Disrupts Boston Scientific’s Operations: 7 Things to Know appeared first on MedCity News.

FDA approval of Revolution Medicines’ daraxonrasib, brand name Rasonque, makes the molecule the first RAS inhibitor approved for treating pancreatic adenocarcinoma, the most common type of pancreatic cancer. The speedy regulatory nod specifically covers advanced cases of this type of cancer, which has had limited treatment options. The post Revolution Medicines Receives Landmark FDA Drug Approval in Pancreatic Cancer appeared first on MedCity News.

Health-tech pilots don’t usually fail because the product is bad. They fail because the system was never wired to absorb it. The post Stop Pitching the Institute — Pitch the Stack appeared first on MedCity News.